Description
Temirazer is a combinational drug comprising of Tenofovir disoproxil fumarate 300 mg and Emtricitabine 200 mg. It is a fixed-dose combination (FDC) drug used for managing patients with HIV-1 infection and HIV-1 Pre-Exposure Prophylaxis (PrEP). Temirazer (Tenofovir disoproxil fumarate + Emtricitabine) is utilized in combination with other antiretroviral agents in adults and children weighing greater than 35 kgs.
Prior testing before initiating Temirazer (Tenofovir disoproxil fumarate + Emtricitabine)
- • Testing for Hepatitis B viral infection
- • Testing for chronic kidney disease
- • Testing for HIV-1 PrEP
Based on the body weight and age of the patients, Temirazer (Tenofovir disoproxil fumarate + Emtricitabine) has varied dosage regimens. The recommended dosage is 1 tablet (Tenofovir disoproxil fumarate 300 mg + Emtricitabine 200 mg) which is taken orally with or without food wherein,
- • For adults, 1 dose once daily is recommended
- • For children over 12 years of age and weight greater than 35 kgs, the same dose is given
- • For kidney failure patients (Creatinine clearance: 30-49 mL/min), 1 dose in every 48 hours is administered
- • For HIV-1 uninfected adults, 1 dose once daily is recommended
- • For PrEP, 1 dose once daily with safer sex practices can be employed
Warnings and precautions:
There are certain conditions wherein patients should understand all the necessary details like,
- • Discontinuation of Temirazer (Tenofovir disoproxil fumarate + Emtricitabine) leads to severe acute complications in the liver with Hepatitis B viral infection
- • There are chances of procuring acute kidney failure due to one of the components of the drug
- • Do not use other drugs containing the same molecules (tenofovir disoproxil fumarate and emtricitabine) or other molecules (Efavirenz, Rilpivirine, and Lamivudine) alone or in combination
- • In some advanced HIV infected patients, there are chances of inflammation occurring due to immune reconstitution syndrome
- • Patients are seen with decreased bone mineral density (Weakened bones)
- • In a few cases, the patients gain an excessive amount of lactic acid in the blood (lactic acidosis) which may lead to hepatoxicity
- • Patients should confirm if they are negative for HIV-1 infection before starting the drug for HIV-1 PrEP therapy
- • Use all possible contraceptive methods for preventing the transmission of new HIV-1 infection
Side-effects of Temirazer (Tenofovir disoproxil fumarate + Emtricitabine)
Most common side-effects in HIV-1 infected patients:
- • Diarrhea
- • Tiredness (Fatigue)
- • Dizziness
- • Atypical dreams
- • Difficulty in sleeping (Insomnia)
- • Depression
- • Headache
- • Rashes on the skin
- • Nausea
Most common side-effects in patients who took the drug to reduce the risk of getting HIV-1 infection:
- • Pain in the abdomen (stomach area)
- • Loss of weight
- • Headache
Note: Temirazer (Tenofovir disoproxil fumarate + Emtricitabine) may show other side effects too; consult your doctor for more information.
